.png){kind=icon}
返回
Umbralisib: First Approval
.png){kind=icon}
PRE
AI
DOI：10.1007/s40265-021-01504-2.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Umbralisib (UKONIQ (TM)) is an oral, first-in-class dual phosphatidylinositol 3-kinase delta (PI3K delta) and casein kinase 1 epsilon (CK1 epsilon) inhibitor being developed by TG Therapeutics for the treatment of various haematological malignancies. In February 2021, umbralisib received its first approval in the USA for the treatment of adults with relapsed or refractory marginal zone lymphoma (MZL) who have received >= 1 prior anti-CD20-based regimen, and relapsed or refractory follicular lymphoma (FL) who have received >= 3 prior lines of systemic therapy. Clinical studies in various haematological malignancies, including chronic lymphocytic leukaemia and non-Hodgkin's lymphoma, are underway in multiple countries. This article summarizes the milestones in the development of umbralisib leading to this first approval.
Keyword:
PI3K-DELTA INHIBITOR
BRENTUXIMAB VEDOTIN
LYMPHOMA
TGR-1202
AI总结
对已上传原文的论文进行重点信息的提取，主要内容包括：简要概述、研究摘要、背景介绍、关键亮点、图文解析、展望与总结。
期刊
IF:
14.4
论文数:
8.4K
被引数:
2.3W
机构
暂无机构信息
引用论文
Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.png)
LANCET HAEMATOLOGY
OAAI
LANCET HAEMATOLOGYIF17.7
OAAI分享收藏Lack of Electron Acceptors Contributes to Redox Stress and Growth Arrest in Asparagine-Starved Sarcoma CellsCancersOAAI
CancersIF0
OAAI分享收藏The novel PI3K-δ inhibitor TGR-1202 enhances Brentuximab Vedotin-induced Hodgkin lymphoma cell death via mitotic arrestLEUKEMIAOAAI
LEUKEMIAIF13.4
OAAI分享收藏The dual PI3Kδ/CK1ε inhibitor umbralisib exhibits unique immunomodulatory effects on CLL T cellsBLOOD ADVANCESOAAI
BLOOD ADVANCESIF7.1
OAAI分享收藏
查看更多内容